Amarin Corp. (AMRN) option implied volatility elevated into sharp rally on release of patient study
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Amgen (AMGN) Rumored as Potential Amarin (AMRN) Suitor
September 24, 2018 12:51 PM EDTChatter Amgen (NASDAQ: AMGN) could be looking to acquire Amarin Corp. (NASDAQ: AMRN), according to STAT's Adam Feuerstein (LINK)
Amarin Corporation (AMRN) PT Raised to $15 at Cantor Fitzgerald
September 24, 2018 10:05 AM EDTCantor Fitzgerald analyst Louise Chen raised the price target on Amarin Corporation (NASDAQ: AMRN) to $15.00 (from $10.00) while maintaining a Overweight rating.
The raised PT is the result of Chen increasing her estimates for peak sales for Vascepa to $1.1 billion from $648.2 million.... More
Amarin (AMRN) Isn't Focused on Selling Company, Management Says of Conf. Call - Bloomberg
September 24, 2018 8:39 AM EDTAmarin Corp. (NASDAQ: AMRN) Isn't Focused on Selling Company, Management Says of Conf. Call - Bloomberg
... MoreAmarin Corp. (AMRN) Surges 278% on Positive Study Results
September 24, 2018 6:31 AM EDTAmarin Corp. (NASDAQ: AMRN) is surging 278% in pre-open trade after the company announced topline results from the Vascepa® cardiovascular (CV) outcomes trial, REDUCE-IT, a global... More
